Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Ando K, Emi Y, Miyanari N, Tsuji A, Sakai K, Sawai T, Imamura H, Mori S, Tokunaga S, Oki E, Saeki H, Kakeji Y, Akagi Y, Baba H, Maehara Y, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Among authors: akagi y. Int J Clin Oncol. 2020 Jun;25(6):1115-1122. doi: 10.1007/s10147-020-01646-5. Epub 2020 Mar 18. Int J Clin Oncol. 2020. PMID: 32189156 Clinical Trial.
Predicting oncologic outcomes by stratifying mesorectal extension in patients with pT3 rectal cancer: a Japanese multi-institutional study.
Akagi Y, Shirouzu K, Fujita S, Ueno H, Takii Y, Komori K, Ito M, Sugihara K; Study Group of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) on the Clinical Significance of the Mesorectal Extension of Rectal Cancer. Akagi Y, et al. Int J Cancer. 2012 Sep 1;131(5):1220-7. doi: 10.1002/ijc.27315. Epub 2012 Jan 3. Int J Cancer. 2012. PMID: 22025276
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Emi Y, et al. Among authors: akagi y. Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13. Int J Clin Oncol. 2013. PMID: 22240888
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Oki E, et al. Among authors: akagi y. Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31. Oncology. 2013. PMID: 23392220 Clinical Trial.
637 results